Online Inquiry

RDC as Imaging Tools

By conjugating cancer-targeted molecules with radionuclides for imaging, RDC can be used as a very important imaging tool in scientific research.

  • Researches Requiring Imaging Technology
    RDC (Radionuclide Drug Conjugate) has a wide range of applications in in vitro and in vivo imaging. It can be used not only for clinical cancer diagnosis and efficacy detection but also as an imaging tool for detection, characterization, and monitoring of cell line models and animal models, providing a bridge from laboratory animals ultimately to humans with the goal to promote the cancer research in clinical.
  • Uniqueness of RDC Imaging
    The essential reason for applying RDC as an imaging agent in animal models is to obtain comprehensive information from a cancer-bearing animal. Compared to other analysis methods in animal models, the advantage of RDC applied in in vivo imaging is the ability to study the structure, metabolism, and function of cancer cells, and the biodistribution of potential radiopharmaceutical without the need for necropsy, which ensures the repetitive studies can be performed in the same animals, with each animal serving as its own control.


  • The Importance of SPECT/PET Imaging
    Nuclear medicine images are produced by intravenous injection of short-lived radioactive isotopes into the animals, and then detecting their decay using a gamma camera, such as SPECT (Single Photon Emission Computed Tomography) or PET (Positron Emission) scanner, revealing the spatial and temporal distribution of target-specific radiotracers and pharmaceuticals. Even though both imaging modalities via RDC have a relatively low spatial resolution, the sensitivity of these two approaches is extremely high with subtle effects on experimental animals, which can reveal properties such as glucose metabolism, blood volume and flow, tissue uptake, receptor binding, and oxygen utilization.
  • RDC for SPECT/PET Imaging
    As one essential part of RDC, the vector molecule, including antibody, small molecule, and peptide, can target specific molecules and gather at the targeting cells to image by PET or SPECT to visualize the specific molecular targets. As radiopharmaceutical probes, RDC is radiolabeled by different types of radioactive particles, 64Cu, 68Ga, 89Zr for PET and 99mTc, 201Ti, 111In for SPECT.

Diving line.

99mTc- 3PRGD2 for Drug Evaluation

CM (Choroidal Melanoma) is a deadly malignancy with increasing incidence and burden worldwide, which may be caused by a variety of reasons, such as family history. The development of novel therapies for melanoma has received a great deal of attention. In order to more effectively evaluate the effects of novel drugs and therapies on CM, 99mTc-PEG4-E[PEG4-c(RGDfK)]2 (99mTc-3PRGD2), a novel RDC, is applied to clinical imaging via SPECT/CT with excellent quality in all 10 patients with a clear background, which is a key point for accuracy discrimination of CM lesions.

99mTc-3PRGD2 SPECT/CT images and CDFI images in a 78-year-old woman with CM.Fig.1 99mTc-3PRGD2 SPECT/CT images and CDFI images in a 78-year-old woman with CM. (Yan, B., et al., 2018, Medicine)

[64Cu]DOTA-KJ1-26 mAbs for T Cell Labeling

T cells play an important role in inflammation, autoimmune diseases, and immunotherapy, of which the temporal distribution and homing dynamics in mammals are of special interest. A special RDC, 64Cu-mAb (Monoclonal Antibody), can target the TCR (T Cell Receptor) and further radiolabel T cells for examination of the T cell migration kinetics, homing patterns, and the sites of T cell proliferation and activation to promote understanding of the T cell response in a non-invasive way.

Schematic principle of the in vitro labeling of cOVA-TCRtg-TH1 cells with cOVA-TCR–specific [64Cu]DOTAKJ1-26 mAbs.Fig.2 Schematic principle of the in vitro labeling of cOVA-TCRtg-TH1 cells with cOVA-TCR–specific [64Cu]DOTAKJ1-26 mAbs. (Griessinger, C. M., et al., 2015, Proc Natl Acad Sci U S A.)

Our Service

With top-notched precision platforms and experienced scientists, Rdcthera can offer cost-effective and high-quality RDC-related services, including RDC development and analysis services for worldwide clients. We are honored to share our technology and information with you. Please contact us for more information.


  1. Yan, B., Fu, T., Liu, Y., Wei, W., Dai, H., Fang, W., & Wang, F. (2018). 99mTc-3PRGD2 single-photon emission computed tomography/computed tomography for the diagnosis of choroidal melanoma: A preliminary STROBE-compliant observational study. Medicine, 97(40).
  2. Griessinger, C. M., Maurer, A., Kesenheimer, C., Kehlbach, R., Reischl, G., Ehrlichmann, W., ... & Kneilling, M. (2015). 64Cu antibody-targeting of the T-cell receptor and subsequent internalization enables in vivo tracking of lymphocytes by PET. Proceedings of the National Academy of Sciences, 112(4), 1161-1166.
For research use only. Not intended for any clinical use.

Rdcthera RDC

Rdcthera offers efficient, customized, and professional R&D services related to radionuclide drug conjugates.

Copyright © Rdcthera. All rights reserved. Privacy Policy | Cookie Policy